Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 11:15:1403147.
doi: 10.3389/fphar.2024.1403147. eCollection 2024.

Cannabidiol, a plant-derived compound, is an emerging strategy for treating cognitive impairments: comprehensive review of randomized trials

Adriana Yndart Arias #  1   2 , Kamila Vadell #  2 , Arti Vashist  2 , Nagesh Kolishetti  2 , Madepalli K Lakshmana  2 , Madhavan Nair  2 , Juan P Liuzzi  1
Affiliations
Review

Cannabidiol, a plant-derived compound, is an emerging strategy for treating cognitive impairments: comprehensive review of randomized trials

Adriana Yndart Arias et al. Front Pharmacol. .

Abstract

Background: Finding new strategies to treat cognitive disorders is a challenging task. Medication must defeat the blood-brain barrier. Cannabidiol (CBD), a non-intoxicating compound of the cannabis plant, has gained recognition as a nutraceutical for its potential effectiveness in treating anxiety, oxidative stress, convulsions, and inflammation. However, the dose, tolerable upper intake, formulation, administration routes, comorbidities, diet, and demographic factors to reverse cognitive impairments have not been completely explored. Trials using CBD as a primary intervention have been conducted to alleviate cognitive issues. This review evaluates the benefits of CBD supplementation, research design, formulations, and outcomes reported in randomized clinical trials.

Methods: An evidence-based systematic literature review was conducted using PUBMED and the Florida International University Research Library resources. Fourteen randomized trials were selected for review, and their designs and outcomes were compared conceptually and in the form of resume tables.

Results: CBD showed improvement in anxiety and cognitive impairments in 9 out of 16 analyzed trials. However, the variability could be justified due to the diversity of the trial designs, underpowered studies, assayed population, uncontrolled results for comorbidities, medications, severity of drug dependence, compliances, and adherences. Overall, oral single doses of 200 mg-1,500 mg or vaporized 13.75 mg of CBD were shown to be effective at treating anxiety and cognition with a good safety profile and no drug addiction behaviors. Conversely, results that did not have a significant effect on treating cognitive impairments can be explained by various factors such as THC or other abuse drugs masking effect, low dose, and unknown purity of CBD. Furthermore, CBD shows potential properties that can be tested in the future for Alzheimer's disease.

Conclusion: As medical cannabis becomes more accessible, it is essential to understand whether medication rich in CBD exerts a beneficial effect on cognitive disorders. Our study concludes that CBD is a promising candidate for treating neurocognitive disorders; however, more studies are required to define CBD as a therapeutic candidate for managing cognitive disorders.

Keywords: Alzheimer’s disease; CBD; anxiety; cannabidiol; clinical trial; cognition; drug of abuse; neurocognitive disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

None
Created with Biorender.com.
FIGURE 1
FIGURE 1
Consort flow diagram.
See this image and copyright information in PMC

References

    1. ADAA (2024). Anxiety disorders - facts and statistics. Available at: https://adaa.org/understanding-anxiety/facts-statistics.
    1. Alvi T., Kumar D., Tabak B. A. (2022). Social anxiety and behavioral assessments of social cognition: a systematic review. J. Affect. Disord. 311, 17–30. 10.1016/j.jad.2022.04.130 - DOI - PMC - PubMed
    1. AND (2022). Evidence analysis manual.
    1. Arkell T. R., Vinckenbosch F., Kevin R. C., Theunissen E. L., McGregor I. S., Ramaekers J. G. (2020). Effect of cannabidiol and Δ9-tetrahydrocannabinol on driving performance: a randomized clinical trial. Jama 324 (21), 2177–2186. 10.1001/jama.2020.21218 - DOI - PMC - PubMed
    1. Augustin S. M., Lovinger D. M. (2022). Synaptic changes induced by cannabinoid drugs and cannabis use disorder. Neurobiol. Dis. 167, 105670. 10.1016/j.nbd.2022.105670 - DOI - PMC - PubMed

LinkOut - more resources